Article
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
The Lancet. Oncology - 1 Sept 2016
Brose Marcia S, Cabanillas Maria E, Cohen Ezra E W, Wirth Lori J, Riehl Todd, Yue Huibin, Sherman Steven I, Sherman Eric J
Abstract excerpt
BACKGROUND: About half of patients with papillary thyroid cancer have tumours with activating BRAF(V600E) mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAF(V600E)-positive papillary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.